Dermbits

Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions
What’s one documentation habit that consistently improves approvals?
1:24
Mar 2, 2026Atopic Dermatitis

What’s one documentation habit that consistently improves approvals?

-

How do you document steroid failure before prescribing ruxolitinib cream?
1:40
Mar 2, 2026Atopic Dermatitis

How do you document steroid failure before prescribing ruxolitinib cream?

-

What helps secure coverage for ruxolitinib in step therapy plans?
1:33
Mar 2, 2026Atopic Dermatitis

What helps secure coverage for ruxolitinib in step therapy plans?

-

What documentation details helps support approval for ruxolitinib cream?
0:59
Feb 2, 2026Topical Therapies

What documentation details helps support approval for ruxolitinib cream?

-

Can EHR templates improve access for new therapies like ruxolitinib?
0:43
Feb 2, 2026Topical Therapies

Can EHR templates improve access for new therapies like ruxolitinib?

-

What are common documentation mistakes that delay access to newer topicals?
0:53
Feb 2, 2026Topical Therapies

What are common documentation mistakes that delay access to newer topicals?

-

What’s key to documenting steroid failure or intolerance clearly?
1:10
Feb 2, 2026Topical Therapies

What’s key to documenting steroid failure or intolerance clearly?

-

How do you talk to patients when access issues delay treatment?
1:18
Feb 2, 2026Topical Therapies

How do you talk to patients when access issues delay treatment?

-

What’s your top access tip for new clinicians balancing care and paperwork?
1:11
Feb 2, 2026Topical Therapies

What’s your top access tip for new clinicians balancing care and paperwork?

-

How does the MyPath Melanoma test differ from standard histopathologic evaluation?
1:12
Dec 19, 2025Cutaneous Melanoma

How does the MyPath Melanoma test differ from standard histopathologic evaluation?

-

When should dermatologists consider the use of MyPath Melanoma test for a suspicious lesion?
1:20
Dec 19, 2025Cutaneous Melanoma

When should dermatologists consider the use of MyPath Melanoma test for a suspicious lesion?

-

How should MyPath Melanoma test results be interpreted, especially when the result is not clearly benign or malignant?
0:57
Dec 19, 2025Cutaneous Melanoma

How should MyPath Melanoma test results be interpreted, especially when the result is not clearly benign or malignant?

-

What logistical considerations should dermatologists keep in mind when ordering MyPath Melanoma?
1:00
Dec 19, 2025Cutaneous Melanoma

What logistical considerations should dermatologists keep in mind when ordering MyPath Melanoma?

-

In what clinical scenarios might a dermatologist consider ordering MyPath Melanoma for a melanocytic lesion?
1:22
Dec 19, 2025Cutaneous Melanoma

In what clinical scenarios might a dermatologist consider ordering MyPath Melanoma for a melanocytic lesion?

-

Can you describe how MyPath Melanoma adds clinical value when evaluating melanocytic lesions that are not clearly malignant?
1:26
Dec 19, 2025Cutaneous Melanoma

Can you describe how MyPath Melanoma adds clinical value when evaluating melanocytic lesions that are not clearly malignant?

-

How does a positive or negative MyPath Melanoma result impact your treatment recommendations?
1:27
Dec 19, 2025Cutaneous Melanoma

How does a positive or negative MyPath Melanoma result impact your treatment recommendations?

-

What role do you see molecular diagnostics playing in the early detection and management of melanoma over the next 5 to 10 years?
1:03
Dec 19, 2025Cutaneous Melanoma

What role do you see molecular diagnostics playing in the early detection and management of melanoma over the next 5 to 10 years?

-

What makes some melanocytic lesions difficult to diagnose based on histopathology alone?
0:56
Dec 19, 2025Cutaneous Melanoma

What makes some melanocytic lesions difficult to diagnose based on histopathology alone?

-

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology? With Dr. Moody
1:13
Dec 19, 2025Cutaneous Melanoma

What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology? With Dr. Moody

-

What makes a sunscreen well formulated from both a clinician and patient perspective?
1:44
Nov 14, 2025Sunscreen

What makes a sunscreen well formulated from both a clinician and patient perspective?

-

How do ingredients beyond UV filters, like antioxidants or moisturizers, enhance photoprotection?
0:48
Nov 14, 2025Sunscreen

How do ingredients beyond UV filters, like antioxidants or moisturizers, enhance photoprotection?

-

How do you identify sunscreens that offer reliable broad-spectrum protection beyond SPF ratings?
1:07
Nov 14, 2025Sunscreen

How do you identify sunscreens that offer reliable broad-spectrum protection beyond SPF ratings?

-

What makes a sunscreen particularly effective for pigment protection or visible-light defense?
0:59
Nov 14, 2025Sunscreen

What makes a sunscreen particularly effective for pigment protection or visible-light defense?

-

What is Helioplex technology, and how does it improve stability and UV coverage?
0:52
Nov 14, 2025Sunscreen

What is Helioplex technology, and how does it improve stability and UV coverage?

-